Biohacker Network
PeptidesEvidence: Preclinical-dominant

How to Take BPC-157: Routes, Study Methods & the Capsule Question

Written by
Daniel Reyes, PhD
Medically reviewed by
Dr. Sarah Lindqvist, MD
Published
June 20, 2025
Updated
June 20, 2025
Last medical review
June 20, 2025
Reviewer scope
Metabolic health
Amber gel capsules representing oral BPC-157 products, a commercial format with essentially no published outcome data of its own

BPC-157 has been administered three ways in research: subcutaneous or intramuscular injection, orally in drinking water (rodents), and — commercially but almost never in studies — capsules. The peptide is unusually stable in gastric juice, which makes oral routes biologically plausible for gut endpoints, but systemic effects from capsules remain unproven anywhere. Route selection and dosing are clinical decisions; the compound remains unapproved.

What each route actually has behind it

  • Injection (subcutaneous/IM): the dominant route in rodent tendon and muscle studies
  • Oral solution: used in rodent gut-injury models, where a gastric peptide plausibly acts locally
  • Capsules: a commercial format with essentially no published outcome data of its own
Clinician preparing a subcutaneous injection in a dim lab — injection was the dominant route in BPC-157 rodent tendon and muscle studies

The stability argument, honestly stated

BPC-157 derives from a gastric-juice protein and resists degradation in stomach acid — a real and unusual property. Stability in acid is not the same as systemic bioavailability to a tendon in a human. That leap has never been measured.

Route determines which claims are even plausible — the oral vs injectable comparison maps each claim to its evidence trail. Dose numbers are dissected in the dosage research review and duration folklore in the cycle-length analysis. The full compound profile lives in our BPC-157 monograph.

Injection-site basics if a clinician prescribes it

Sterile technique per USP <797> handling principles, site rotation, and pharmacy-labeled storage. This page reports what published studies and regulatory documents describe. It never recommends a dose — dosing is a clinical decision for a licensed prescriber who knows your history.

Frequently asked questions

Can you take BPC-157 orally?
Rodent studies used oral BPC-157 in drinking water for gut-injury models, where a stomach-derived peptide plausibly acts locally. The peptide is unusually stable in gastric juice, but systemic effects from oral use — reaching a tendon, for example — have never been demonstrated in humans.
Do BPC-157 capsules work?
Capsules are a commercial format with essentially no published outcome data of their own. Gastric stability makes oral routes plausible for gut endpoints, but no capsule product has human evidence for any outcome, and content verification is a separate unsolved problem.
How is BPC-157 injected in studies?
Rodent soft-tissue studies used subcutaneous or intramuscular injection. If a clinician ever prescribes it, sterile technique per USP <797> principles, site rotation, and pharmacy-labeled storage apply — and the dose and site plan come from the prescriber.

Questions to ask a licensed clinician

  • Does my goal (gut vs soft tissue) change which route has any plausibility?
  • How would we verify what a capsule product even contains?

References

  1. Sikiric P, Seiwerth S, Rucman R, et al. (2018). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. SourceNarrative review
  2. Chang CH, Tsai WC, Lin MS, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. SourcePreclinical
  3. US Pharmacopeia (2023). General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP-NF. SourceStandard

Related tools

Related guides

Something incorrect in this guide? Report a correction. Material corrections are noted on the page with the date and nature of the change.